Cartagena Protocol on Biosafety

Genetic engineering logo

The Cartagena Protocol on Biosafety is an international treaty that aims to ensure the safe handling, transport, and use of living modified organisms (LMOs) resulting from modern biotechnology that may have adverse effects on biological diversity. The protocol was adopted on January 29, 2000, in Cartagena, Colombia, and entered into force on September 11, 2003.

The main objective of the Cartagena Protocol is to contribute to the protection of biological diversity by establishing clear procedures for the safe transfer, handling, and use of LMOs. It recognizes the potential risks posed by LMOs to the environment and human health and seeks to address these risks through the implementation of appropriate measures.

Key provisions of the protocol include the advance informed agreement (AIA) procedure, which requires exporters to obtain consent from importing countries before shipping LMOs, and the development of risk assessment and management procedures to evaluate the potential environmental impacts of LMOs.

The Cartagena Protocol also promotes public awareness and participation in decision-making processes related to biosafety issues. It encourages transparency and information sharing among countries to facilitate the exchange of scientific, technical, and regulatory information on LMOs.

In addition, the protocol establishes a Biosafety Clearing-House (BCH) to facilitate the exchange of information on LMOs and assist countries in implementing the protocol's provisions. The BCH serves as a central repository for information on LMOs, including details on risk assessments, regulatory decisions, and other relevant data.

Overall, the Cartagena Protocol on Biosafety plays a crucial role in promoting the safe use of modern biotechnology and protecting biological diversity. By fostering international cooperation and collaboration, the protocol helps countries to address the challenges posed by LMOs and ensure the sustainable management of biodiversity.